In treating mild persistent asthma for children aged 5-11, which one of the following is included?

In the management of mild persistent asthma in children aged 5-11, the recommended treatment includes a low-dose inhaled corticosteroid (ICS). Low-dose ICS is effective in reducing inflammation in the airways, thereby helping to control chronic symptoms and prevent exacerbations. For children, this approach aligns with the guidelines, which emphasize the importance of using ICS as a first-line medication for mild persistent cases to achieve better asthma control over time.

While medium-dose ICS can be used for more severe forms of asthma, it is not typically the starting choice for mild cases due to concerns about potential side effects at higher doses. Long-acting beta-agonists (LABAs) are generally not recommended as monotherapy and typically accompany ICS therapy for moderate to severe asthma, not for mild persistent cases. Cromolyn can be considered in some treatment scenarios, but it is generally regarded as less effective than low-dose ICS for persistent asthma management. Therefore, the correct choice in this context is low-dose ICS, as it directly addresses the inflammatory component of asthma in a safe and effective manner for this age group.